Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/8/2026

First‑Line Preventive Medications for Episodic Migraine

  • Candesartan 16 mg once daily (or telmisartan 80 mg once daily) is given a strong recommendation by the 2024 Veterans Affairs/Department of Defense (VA/DoD) migraine prevention guideline. [1][2]
  • Candesartan provides added benefit in patients who also have hypertension, offering dual control of blood pressure and migraine frequency. 2
  • Propranolol 80–240 mg daily (most commonly 160 mg daily) is FDA‑approved and supported by strong evidence from multiple randomized trials. [1][2]
  • Timolol 20–30 mg daily also carries strong evidence for migraine prophylaxis. [1][2]
  • Metoprolol is an alternative beta‑blocker with moderate‑quality evidence supporting its use. 1

2. CGRP Monoclonal Antibodies

  • Erenumab, fremanezumab, and galcanezumab receive strong recommendations from the 2024 VA/DoD guideline for both episodic and chronic migraine prevention. [1][2]
  • The 2025 American College of Physicians (ACP) guideline places CGRP monoclonal antibodies as second‑line therapy, to be used after failure of beta‑blockers, valproate, venlafaxine, or amitriptyline. 3
  • Eptinezumab (IV formulation) is given a weak recommendation for episodic or chronic migraine by the 2024 VA/DoD guideline. [1][2]

3. Oral CGRP Antagonists (Gepants)

  • Atogepant (10 mg, 30 mg, or 60 mg once daily) is FDA‑approved for episodic migraine prevention (60 mg dose for chronic migraine). 1
  • Rimegepant lacks sufficient evidence in the 2024 VA/DoD guideline but receives a weak recommendation from the 2025 ACP guideline. [1][3]2

4. Second‑Line Oral Agents

  • Topiramate 50–100 mg daily (typically divided twice daily) carries a weak recommendation for both episodic and chronic migraine. [1][2]
  • Valproate (800–1500 mg daily) or divalproex sodium (500–1500 mg daily) have weak recommendations but are absolutely contraindicated in women of child‑bearing potential because of teratogenic risk. [1][2]
  • Amitriptyline 30–150 mg daily is preferred when comorbid depression, anxiety, or sleep disturbance is present; evidence is stronger for episodic than chronic migraine. 1
  • Lisinopril, oral magnesium, and memantine each receive a weak recommendation for episodic migraine prevention. [1][2]

5. Dosing Highlights

  • Propranolol: start 80 mg daily, titrate to 160–240 mg daily; most patients need ≥160 mg for therapeutic effect. 1
  • Timolol: 20–30 mg daily. [1][2]
  • Eptinezumab: 100 mg IV every 3 months. [1][2]

6. Safety and Contraindications

  • Valproate/divalproex: strictly contraindicated in women of child‑bearing potential due to risk of neural‑tube defects and developmental delays. [1][3]2

7. Patient Selection for Preventive Therapy

  • Initiate preventive therapy when a patient experiences ≥2 migraine attacks per month with disability lasting ≥3 days. 1
  • Limit acute medication use to ≤2 days per week to avoid medication‑overuse headache. [1][3]

8. Algorithmic Choice Based on Comorbidities

  • Hypertension present → start candesartan 16 mg daily. 2
  • No beta‑blocker contraindications → start propranolol 80–240 mg daily. [1][2]

9. Escalation Strategy

  • After failure of two oral preventives (e.g., propranolol and topiramate), escalate to CGRP monoclonal antibodies or atogepant. 3
  • The 2025 ACP guideline advises trying beta‑blockers, valproate, venlafaxine, or amitriptyline before moving to CGRP therapies. 3

10. Practices to Avoid

  • Gabapentin is not recommended for episodic migraine prevention by the 2024 VA/DoD guideline. [1][2]
  • OnabotulinumtoxinA should be reserved for chronic migraine (≥15 headache days/month) and not used for episodic migraine. [1][2]

All facts are presented in English, include the guideline‑issuing society, and indicate the strength of the supporting evidence.

Migraine Prevention Medication Recommendations

First-Line Preventive Medications

  • The American College of Physicians recommends candesartan or telmisartan for prevention of episodic migraine 4
  • The American College of Physicians strongly recommends CGRP monoclonal antibodies including erenumab, fremanezumab, or galcanezumab for prevention of both episodic and chronic migraine 4
  • Propranolol (80-240 mg/day) is recommended with a weak recommendation but has established efficacy for migraine prevention 4
  • Topiramate (100 mg/day, typically 50 mg twice daily) is suggested with a weak recommendation for prevention of both episodic and chronic migraine 4

Second-Line Preventive Medications

  • Intravenous eptinezumab is suggested for prevention of episodic or chronic migraine 4
  • Lisinopril is suggested for prevention of episodic migraine 4
  • Oral magnesium is suggested for migraine prevention 4
  • Valproate is suggested for prevention of episodic migraine, but is strictly contraindicated in women of childbearing potential due to teratogenic effects 4
  • Memantine is suggested for prevention of episodic migraine 4
  • Atogepant is suggested for prevention of episodic migraine 4
  • OnabotulinumtoxinA injection is suggested specifically for prevention of chronic migraine (but not recommended for episodic migraine) 4

Medications to Avoid

  • Gabapentin is not recommended for prevention of episodic migraine 4
  • AbobotulinumtoxinA or onabotulinumtoxinA injections are not recommended for prevention of episodic migraine 4
  • Galcanezumab is not recommended for prevention of chronic cluster headache 4